بررسی تولید محصولات اصلی و ناخالصی‌های تولید شده در فرایند پرتودهی رنیم طبیعی در رآکتور تهران و مقایسه آن با روش شبیه‌سازی با MCNPX

رنجبر, حسن; پورحبیب, زهرا; بوستانی, احسان

doi:10.24200/nst.2021.1177

نوع مقاله : مقاله پژوهشی

نویسندگان

¹ پژوهشکده چرخه سوخت هسته‌ای، پژوهشگاه علوم و فنون هسته‌ای، سازمان انرژی اتمی ایران، صندوق پستی: 8486-11365، تهران ـ ایران

² دانشکده فیزیک، دانشگاه پیام نور، صندوق پستی: 4697-19395، تهران- ایران

³ پژوهشکده‌ی‌ راکتور و ایمنی هسته‌ای، پژوهشگاه علوم و فنون هسته‌ای، صندوق پستی: 1339-14155، تهران ـ ایران

https://doi.org/10.24200/nst.2021.1177

چکیده

با توجه به این واقعیت که رادیوداروها ترکیبات رادیواکتیو هستند، قوانین و مقررات سختگیرانهای در مورد جنبه‌های کنترل کیفی آن‌ها وجود دارد. یکی از پارامترهای اساسی در کنترل کیفی، تعیین نوع و میزان ناخالصی در رادیوداروها به منظور اطمینان از تجویز دز صحیح است. مقادیر ناخالصی معمولاً کم است، اما همین مقادیر کم نیز مهم هستند و باید با دقت بالا اندازه‌گیری شوند. هدف از این مطالعه ارزیابی تولید هم‌زمان رنیم-186 و رنیم-188 با یک ماده هدف و بررسی تولید ناخالصی‌های احتمالی است. برای دستیابی به هدف این تحقیق، کار در دو مرحله انجام شد. در فاز اول، مدلی مبتنی بر کد MCNPX برای شبیه‌سازی پرتودهی هدف در رآکتور تحقیقاتی تهران طراحی شد. در فاز دوم، ارزیابی تجربی با استفاده از پرتودهی رنیم طبیعی در رآکتور تحقیقاتی تهران انجام گرفت. نتایج شبیه‌سازی و عملی (تجربی) نشان داد که رنیم-186 و رنیم-188 می‌توانند به طور هم‌زمان و با اکتیویته مناسب و تقریباً برابر تولید شوند. هم‌چنین میزان ناخالصی‌ها در مقایسه با محصولات اصلی بسیار ناچیز است. یافته‌های ما نشان داد که داده‌های تجربی با داده‌های شبیه‌سازی مطابقت خوبی دارند (اختلاف کم‌تر از 5%) و در نتیجه، روش شبیه‌سازی روش قدرتمند و مفیدی برای بررسی جنبه‌های مختلف تولید رادیوایزوتوپ در رآکتورهای تحقیقاتی است.

کلیدواژه‌ها

20.1001.1.17351871.1399.41.4.17.2

عنوان مقاله [English]

Investigation of production of main products and impurities in irradiation process of natural rhenium in Tehran reactor and comparison with simulation method by MCNPX

نویسندگان [English]

H. Ranjbar ¹
Z. Pourhabib ²
E. Boustani ³

¹ Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 11365-8486, Tehran – Iran

² Department of Physics, Payame Noor University, P.O. Box: 19395-4697, Tehran-Iran

³ Reactor and Nuclear Safety Research School, Nuclear Science and Technology Research Institute, P.O.Box: 14155-1339, Tehran - Iran

چکیده [English]

Considering the radioactivity of radiopharmaceuticals compounds, there are strict rules and regulations regarding their quality control aspects. One of the essential parameters in quality control is to determine the type and amount of radiopharmaceuticals impurities in order to ensure the prescribing of the correct dose. Impurity values are usually small, but these small amounts are also important and should be measured with high accuracy. The purpose of this study is to evaluate the simultaneous production of ¹⁸⁶Re and ¹⁸⁸Re with one target material and to investigate the production of probable impurities. To achieve the goal of this research, the work was carried out in two phases. In phase 1, a model based on the MCNPX code is designed to simulate target irradiation. In phase 2, the experimental assessment will be carried out using natural rhenium irradiation in Tehran research reactor. Both simulation and practical results showed that ¹⁸⁶Re and ¹⁸⁸Re can be produced with appropriate and nearly equal activities, simultaneously. Also, the amount of impurities is negligible compared to the main products. Our findings indicated that experimental data are in good agreement with simulation data (bias error less than 5%) and as a result, the simulation method is the powerful and useful technique to investigate different aspects of radioisotope production in reactor.

کلیدواژه‌ها [English]

Impurity
Radiopharmaceutical
186Re/188Re cocktail
Tehran research reactor

مراجع

1. E. Seregn, et al., Treatment with tandem [⁹⁰Y] DOTA-TATE and [¹⁷⁷Lu] DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging, 41(2), 223 (2014).

2. J. Kunikowska, et al, Clinical results of radionuclide therapy of neuroendocrine tumours with ⁹⁰Y-Dotatate and tandem ⁹⁰Y/¹⁷⁷Lu-Dotatate: which is a better therapy option?. Eur J Nucl Med Mol Imaging, 38(10), 1788-1797 (2011).

3. H. Ranjbar, et al, Dosimetric evaluation of ¹⁵³Sm-EDTMP, ¹⁷⁷Lu-EDTMP and ¹⁶⁶Ho-EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half-life of radionuclides. Radiat Phys Chem. 108, 60-64 (2015).

4. M. Alavi, et al, ¹⁷⁷Lu/¹⁵³Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases. Cancer biotherapy & radiopharmaceuticals. 34(5), 280-287 (2019).

5. H. Ranjbar, et al, Determination of human absorbed dose of cocktail of ¹⁵³Sm/¹⁷⁷Lu-EDTMP, based on biodistribution data in rats. J. Radioanal Nucl Chem. 307(2), 1439-1444 (2016).

6. P. Unak, B. Cetinkaya, I. Unak, Absorbed dose estimates at the cellular level for ¹⁸⁶Re and ¹⁸⁸Re. Radiat Phys Chem. 73(3), 137-146 (2005).

7. K. Kothari, et al, Preparation, stability studies and pharmacological behavior of [¹⁸⁶Re] Re–HEDP, Applied radiation and isotopes, 51(1), 51-58 (1999).

8. D. Bagatti, et al., Analytical and radioanalytical quality control of purity and stability of radiopharmaceutical compound [^186gRe] Re-HEDP for bone metastases pain palliation. Journal of Radioanalytical and Nuclear Chemistry, 263(2), 515-520 (2005).

9. H. Ranjbar, et al, Development of ¹⁵³Sm/¹⁷⁷Lu-EDTMP as a possible therapeutic complex. Iran J Nucl Med. 25(1), 11-16 (2017).

10. E. Boustani, R. Shahhosseini, M. Hassanzadeh, The use of new irradiation instrument in a pool type research reactor, Progress in Nuclear Energy, 113, 45-52 (2019).

11. E. Boustani, H. Ranjbar, A. Rahimian, Developing a new target design for producing ⁹⁹Mo in a MTR reactor. Applied Radiation and Isotopes, 147, 121-128 (2019).

مجله علوم و فنون هسته ای

بررسی تولید محصولات اصلی و ناخالصی‌های تولید شده در فرایند پرتودهی رنیم طبیعی در رآکتور تهران و مقایسه آن با روش شبیه‌سازی با MCNPX

مراجع

مراجع

1. E. Seregn, et al., Treatment with tandem [⁹⁰Y] DOTA-TATE and [¹⁷⁷Lu] DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging, 41(2), 223 (2014).

2. J. Kunikowska, et al, Clinical results of radionuclide therapy of neuroendocrine tumours with ⁹⁰Y-Dotatate and tandem ⁹⁰Y/¹⁷⁷Lu-Dotatate: which is a better therapy option?. Eur J Nucl Med Mol Imaging, 38(10), 1788-1797 (2011).

3. H. Ranjbar, et al, Dosimetric evaluation of ¹⁵³Sm-EDTMP, ¹⁷⁷Lu-EDTMP and ¹⁶⁶Ho-EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half-life of radionuclides. Radiat Phys Chem. 108, 60-64 (2015).

4. M. Alavi, et al, ¹⁷⁷Lu/¹⁵³Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases. Cancer biotherapy & radiopharmaceuticals. 34(5), 280-287 (2019).

5. H. Ranjbar, et al, Determination of human absorbed dose of cocktail of ¹⁵³Sm/¹⁷⁷Lu-EDTMP, based on biodistribution data in rats. J. Radioanal Nucl Chem. 307(2), 1439-1444 (2016).

6. P. Unak, B. Cetinkaya, I. Unak, Absorbed dose estimates at the cellular level for ¹⁸⁶Re and ¹⁸⁸Re. Radiat Phys Chem. 73(3), 137-146 (2005).

7. K. Kothari, et al, Preparation, stability studies and pharmacological behavior of [¹⁸⁶Re] Re–HEDP, Applied radiation and isotopes, 51(1), 51-58 (1999).

8. D. Bagatti, et al., Analytical and radioanalytical quality control of purity and stability of radiopharmaceutical compound [^186gRe] Re-HEDP for bone metastases pain palliation. Journal of Radioanalytical and Nuclear Chemistry, 263(2), 515-520 (2005).

9. H. Ranjbar, et al, Development of ¹⁵³Sm/¹⁷⁷Lu-EDTMP as a possible therapeutic complex. Iran J Nucl Med. 25(1), 11-16 (2017).

10. E. Boustani, R. Shahhosseini, M. Hassanzadeh, The use of new irradiation instrument in a pool type research reactor, Progress in Nuclear Energy, 113, 45-52 (2019).

11. E. Boustani, H. Ranjbar, A. Rahimian, Developing a new target design for producing ⁹⁹Mo in a MTR reactor. Applied Radiation and Isotopes, 147, 121-128 (2019).

12. D.B. Pelowitz, MCNPXTM user’s manual. Los Alamos National Laboratory, Los Alamos. (2005).

13. Gilmore, Gordon, Practical gamma-ray spectroscopy. John Wiley & Sons, (2011).

دوره 41، شماره 4 - شماره پیاپی 94
دی 1399
صفحه 146-152

بررسی تولید محصولات اصلی و ناخالصی‌های تولید شده در فرایند پرتودهی رنیم طبیعی در رآکتور تهران و مقایسه آن با روش شبیه‌سازی با MCNPX

مراجع

مراجع

1. E. Seregn, et al., Treatment with tandem [90Y] DOTA-TATE and [177Lu] DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging, 41(2), 223 (2014).

2. J. Kunikowska, et al, Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-Dotatate and tandem 90Y/177Lu-Dotatate: which is a better therapy option?. Eur J Nucl Med Mol Imaging, 38(10), 1788-1797 (2011).

3. H. Ranjbar, et al, Dosimetric evaluation of 153Sm-EDTMP, 177Lu-EDTMP and 166Ho-EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half-life of radionuclides. Radiat Phys Chem. 108, 60-64 (2015).

4. M. Alavi, et al, 177Lu/153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases. Cancer biotherapy & radiopharmaceuticals. 34(5), 280-287 (2019).

5. H. Ranjbar, et al, Determination of human absorbed dose of cocktail of 153Sm/177Lu-EDTMP, based on biodistribution data in rats. J. Radioanal Nucl Chem. 307(2), 1439-1444 (2016).

6. P. Unak, B. Cetinkaya, I. Unak, Absorbed dose estimates at the cellular level for 186Re and 188Re. Radiat Phys Chem. 73(3), 137-146 (2005).

7. K. Kothari, et al, Preparation, stability studies and pharmacological behavior of [186Re] Re–HEDP, Applied radiation and isotopes, 51(1), 51-58 (1999).

8. D. Bagatti, et al., Analytical and radioanalytical quality control of purity and stability of radiopharmaceutical compound [186gRe] Re-HEDP for bone metastases pain palliation. Journal of Radioanalytical and Nuclear Chemistry, 263(2), 515-520 (2005).

9. H. Ranjbar, et al, Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex. Iran J Nucl Med. 25(1), 11-16 (2017).

10. E. Boustani, R. Shahhosseini, M. Hassanzadeh, The use of new irradiation instrument in a pool type research reactor, Progress in Nuclear Energy, 113, 45-52 (2019).

11. E. Boustani, H. Ranjbar, A. Rahimian, Developing a new target design for producing 99Mo in a MTR reactor. Applied Radiation and Isotopes, 147, 121-128 (2019).

12. D.B. Pelowitz, MCNPXTM user’s manual. Los Alamos National Laboratory, Los Alamos. (2005).

13. Gilmore, Gordon, Practical gamma-ray spectroscopy. John Wiley & Sons, (2011).

دوره 41، شماره 4 - شماره پیاپی 94دی 1399صفحه 146-152

1. E. Seregn, et al., Treatment with tandem [⁹⁰Y] DOTA-TATE and [¹⁷⁷Lu] DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging, 41(2), 223 (2014).

2. J. Kunikowska, et al, Clinical results of radionuclide therapy of neuroendocrine tumours with ⁹⁰Y-Dotatate and tandem ⁹⁰Y/¹⁷⁷Lu-Dotatate: which is a better therapy option?. Eur J Nucl Med Mol Imaging, 38(10), 1788-1797 (2011).

3. H. Ranjbar, et al, Dosimetric evaluation of ¹⁵³Sm-EDTMP, ¹⁷⁷Lu-EDTMP and ¹⁶⁶Ho-EDTMP for systemic radiation therapy: Influence of type and energy of radiation and half-life of radionuclides. Radiat Phys Chem. 108, 60-64 (2015).

4. M. Alavi, et al, ¹⁷⁷Lu/¹⁵³Sm-Ethylenediamine Tetramethylene Phosphonic Acid Cocktail: A Novel Palliative Treatment for Patients with Bone Metastases. Cancer biotherapy & radiopharmaceuticals. 34(5), 280-287 (2019).

5. H. Ranjbar, et al, Determination of human absorbed dose of cocktail of ¹⁵³Sm/¹⁷⁷Lu-EDTMP, based on biodistribution data in rats. J. Radioanal Nucl Chem. 307(2), 1439-1444 (2016).

6. P. Unak, B. Cetinkaya, I. Unak, Absorbed dose estimates at the cellular level for ¹⁸⁶Re and ¹⁸⁸Re. Radiat Phys Chem. 73(3), 137-146 (2005).

7. K. Kothari, et al, Preparation, stability studies and pharmacological behavior of [¹⁸⁶Re] Re–HEDP, Applied radiation and isotopes, 51(1), 51-58 (1999).

8. D. Bagatti, et al., Analytical and radioanalytical quality control of purity and stability of radiopharmaceutical compound [^186gRe] Re-HEDP for bone metastases pain palliation. Journal of Radioanalytical and Nuclear Chemistry, 263(2), 515-520 (2005).

9. H. Ranjbar, et al, Development of ¹⁵³Sm/¹⁷⁷Lu-EDTMP as a possible therapeutic complex. Iran J Nucl Med. 25(1), 11-16 (2017).

11. E. Boustani, H. Ranjbar, A. Rahimian, Developing a new target design for producing ⁹⁹Mo in a MTR reactor. Applied Radiation and Isotopes, 147, 121-128 (2019).

دوره 41، شماره 4 - شماره پیاپی 94
دی 1399
صفحه 146-152